HiberCell, Inc.
10Patents
9Active
10Granted
48Portfolio score
Filing activity: Mar 14, 2013 → Jan 14, 2022
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US11667651B2 | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | Chemistry; Metallurgy | 1 | Active |
| US11229701B2 | Methods for identifying beta-glucan binding to immune cells | Physics | 1 | Active |
| US11498929B2 | Chromenopyrimidine derivatives as phosphatidylinsitol phosphate kinase inhibitors | Chemistry; Metallurgy | 0 | Active |
| US12331054B2 | Perk inhibiting imidazolopyrazine compounds | Chemistry; Metallurgy | 0 | Active |
| US11815435B2 | Beta glucan immunopharmacodynamics | Physics | 0 | Active |
| US11584763B2 | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | Human Necessities | 0 | Active |
| US11919902B2 | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors | Chemistry; Metallurgy | 0 | Active |
| US12390526B2 | Methods for identifying beta-glucan binding to immune cells | Physics | 0 | Active |
| US11535635B2 | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | General | 0 | Revoked |
| US12006332B2 | Aminopyrimidine derivatives as phosphatidylinositol phosphate kinase inhibitors | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.